Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
9 studies found for:    HCV | Open Studies | Interventional Studies | United States, Florida | Adult | Phase 2, 3, 4
Show Display Options
Rank Status Study
1 Recruiting Study of Oral Treatments for Hepatitis C
Condition: Chronic Hepatitis C
Interventions: Drug: sofosbuvir/ledipasvir;   Drug: ombitasvir/paritaprevir/ritonavir (Phase 1 only);   Drug: elbasvir/grazoprevir;   Drug: Dasabuvir
Age: 18 Years and older   (Adult, Senior)
2 Recruiting Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects
Conditions: Hepatitis C;   HCV
Interventions: Drug: Glecaprevir/Pibrentasvir (G/P) 300mg/120mg;   Drug: Ribavirin 200Mg Tablet
Age: 18 Years to 100 Years   (Adult, Senior)
3 Recruiting A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naïve Adults With Chronic Hepatitis C Virus (HCV) Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis
Condition: Chronic Hepatitis C Virus (HCV)
Intervention: Drug: Glecaprevir/Pibrentasvir
Age: 18 Years to 99 Years   (Adult, Senior)
4 Recruiting Efficacy and Safety of MK-3682B (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)
Conditions: Hepatitis;   Hepatitis C;   Digestive System Diseases;   Flaviviridae Infections;   Hepatitis, Viral, Human;   Liver Diseases;   RNA Virus Infections;   Virus Diseases
Interventions: Drug: MK- 3682B;   Drug: Ribavirin
Age: 18 Years and older   (Adult, Senior)
5 Recruiting Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment Study
Condition: Hepatitis C Virus Infection
Intervention: Drug: SOF/VEL/VOX
Age: 18 Years and older   (Adult, Senior)
6 Recruiting A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment
Condition: Hepatitis C Virus (HCV)
Intervention: Drug: Glecaprevir/Pibrentasvir
Age: 18 Years to 99 Years   (Adult, Senior)
7 Recruiting Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavarin
Condition: Hepatitis C Virus Infection
Interventions: Drug: SOF/VEL;   Drug: RBV
Age: 18 Years and older   (Adult, Senior)
8 Recruiting Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy
Condition: HIV Infections
Interventions: Drug: Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT);   Drug: Dasabuvir (DSV);   Drug: Ribavirin (RBV)
Age: 18 Years to 70 Years   (Adult, Senior)
9 Recruiting A Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab and the Combination Nivolumab Plus Ipilimumab in Patients With Advanced Liver Cancer
Condition: Hepatocellular Carcinoma
Interventions: Biological: Nivolumab;   Drug: Sorafenib;   Drug: Ipilimumab
Age: 18 Years and older   (Adult, Senior)

Study has passed its completion date and status has not been verified in more than two years.